Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are... see more

Recent & Breaking News (NDAQ:ALDX)

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 19, 2023

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)

PR Newswire September 19, 2023

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

TheNewsWire September 18, 2023

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile September 18, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 18, 2023

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Aldeyra Investors of a Lead Plaintiff Deadline of September 29, 2023

PR Newswire September 18, 2023

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

TheNewsWire September 17, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 17, 2023

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

PR Newswire September 16, 2023

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

Newsfile September 15, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action Against Aldeyra Therapeutics, Inc. and Certain Officers - ALDX

Newsfile September 15, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile September 15, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 15, 2023

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire September 14, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile September 14, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 14, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire September 14, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc. and Certain Officers - ALDX

PR Newswire September 13, 2023

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile September 13, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 13, 2023